

Oral Mucosal Absorption: Mechanisms, Methods, and Challenges in Drug Delivery

Ossama M. Sayed ¹

Correspondence:
Ossama M. Sayed
Department of Pharmaceutics,
Faculty of Pharmacy, Sinai
University-Kantara Branch, Ismailia
41612, Egypt
Phone: +20 1066640946
E-mail: osama.sayed@su.edu.eg

¹ Department of Pharmaceutics,
Faculty of Pharmacy, Sinai
University-Kantara Branch, Ismailia
41612, Egypt

Volume number 2
Issue number 5
Pages 155-170

10.61466/ijcmr2050002

Received: 17.06.2024
Accepted: 22.08.2024
Published: 25.08.2024
Online: 01.10.2024

Abstract

This review focuses on the mechanisms and methods involved in oral mucosal absorption, with a particular emphasis on drug delivery systems. It begins by discussing the protective role of saliva in the oral cavity, highlighting its importance in maintaining the health of the oral tissues and facilitating drug delivery. The review then delves into the mechanisms of oral mucosal absorption, including passive diffusion, which is the primary mechanism for drug transfer across the oral mucosa. It also explores the use of hydrophilic polymeric matrices as vehicles for oral transmucosal drug delivery systems, which are favored due to the water-rich environment of the oral cavity. The review further discusses the methods used to assess oral mucosal permeation, including both in vivo and in vitro approaches. In vivo methods, such as the buccal absorption test, are used to determine the bioavailability of drugs via this route, while in vitro methods are employed for high-throughput permeability screening. The review concludes by addressing the challenges and limitations associated with oral mucosal drug delivery, such as the difficulty in studying regional variation in drug absorption and the limitations of in vitro permeability models in predicting in vivo situations.

Keywords: Buccal; Diffusion; Epithelial; mucosa; mucoadhesion; polymers.

Introduction

Most drugs are delivered to the systemic circulation by the conventional oral route; however, the systemic absorption of certain drugs can be significantly hindered by the environment of the gastrointestinal tract. Drugs that are susceptible to acid hydrolysis are substrates for the various efflux mechanisms present in the intestinal wall, or have significant intestinal or hepatic metabolism may exhibit poor bioavailability when administered via the oral route ¹. Buccal drug delivery offers several advantages over the peroral route. These advantages include avoidance of presystemic drug elimination within the gastrointestinal tract and/or during the hepatic first-pass metabolism, and independence from the potential variability of absorption caused by the gastric emptying rate, or the presence of food in the upper region of the gastrointestinal tract ². In addition, the buccal mucosa is relatively permeable with a rich blood supply and has a substantial resistance to irritation or damage ²⁻⁴. Other important advantage is the facility to include permeation enhancer/enzyme inhibitor or pH modifier in the formulation and versatility in designing as multidirectional or unidirectional release systems for local or systemic actions ⁵. The permeability of the buccal mucosa is four to 4,000 times greater than the permeability across skin. As a result, a faster onset of action for several drugs is observed ⁶. A shorter turnover time in the oral mucosa (14 days) as opposed to skin (27 days) ensures a faster recovery of the oral mucosa ⁷.

Absorption through the mucous membranes of the oral cavity was noted as early as 1847 by Sobero, the discoverer of nitroglycerin ⁸, and the systematic studies of oral cavity absorption were first reported by Walton in 1935 and 1944^{9, 10}. Since then, reviews of the subject have been provided by Katz and Barr in 1955¹¹, Gibaldi and Kanig in 1965¹², Squier and Jhonson in 1975¹³, Shojaei in 1998¹⁴ and Junginger, Hoogstraate and Verhoef in 1999¹⁵.

Within the oral mucosal cavity, delivery of drugs is classified into three categories: (i) sublingual delivery, which is systemic delivery of drugs through the mucosal membranes lining the floor of the mouth, (ii) buccal delivery, which is drug administration through the mucosal membranes lining the cheeks (buccal mucosa), and (iii) local delivery, which is drug delivery into the oral cavity.

Structure and Environment of the Oral Mucosa.

Structure:

The oral mucosa is composed of an outermost layer of stratified squamous epithelium (Figure 1). Below this lies a basement membrane, a lamina propria followed by the submucosa as the innermost layer. The epithelium is similar to stratified squamous epithelia found in the rest of the body in that it has a mitotically active basal cell layer, advancing through a number of differentiating intermediate layers to the superficial layers, where cells are shed from the surface of the epithelium¹⁶. The epithelium of the buccal mucosa is about 40-50 cell layers thick, while that of the sublingual epithelium contains somewhat fewer. The epithelial cells increase in size and become flatter as they travel from the basal layers to the superficial layers.




Figure 1. Structure of the oral mucosae. Adapted from reference ¹⁷

The turnover time for the buccal epithelium has been estimated at 5-6 days¹⁷, and this is probably representative of the oral mucosa as a whole. The oral mucosal thickness varies depending on the site: the buccal mucosa measures at 500-800 μm , while the mucosal thickness of the hard and soft palates, the floor of the mouth, the ventral tongue, and the gingivae measure at about 100-200 μm . The composition of the epithelium also varies depending on the site in the oral cavity. The mucosae of areas subject to mechanical stress (the gingivae and hard palate) are keratinized similar to the epidermis. The mucosae of the soft palate, the sublingual, and the buccal regions, however, are not keratinized¹⁷. The keratinized epithelia contain neutral lipids like ceramides and acylceramides which have been associated with the barrier function. These epithelia are relatively impermeable to water. In contrast, non-keratinized epithelia, such as the floor of the mouth and the buccal epithelia do not contain acylceramides and only have small amounts of ceramide¹⁸⁻²⁰. They also contain small amounts of neutral but polar lipids, mainly cholesterol sulfate and glucosyl ceramides. These epithelia have been found to be considerably more permeable to water than keratinized epithelia¹⁷⁻¹⁹.

Permeability:

Galey and coworkers showed that the oral mucosae in general are somewhat leaky epithelia intermediate between that of the epidermis and intestinal mucosa. It is estimated that the permeability of the buccal mucosa is 4-4000 times greater than that of the skin⁶. As indicative by the wide range in this reported value, there are considerable differences in permeability between different regions of the oral cavity because of the diverse structures and functions of the different oral mucosae. In general, Harris D and coworkers showed that the permeabilities of the oral mucosae decrease in the order of sublingual greater than buccal, and buccal greater than palatal¹⁷. This rank order is based on the relative thickness and degree of keratinization of these tissues, with the sublingual mucosa being relatively thin and non-keratinized, the buccal thicker and non-keratinized, and the palatal intermediate in thickness but keratinized.

Gandhi and coworkers stated that the permeability barrier in the oral mucosa is a result of intercellular material derived from the so-called 'membrane coating granules' (MCG)²¹. When cells go through differentiation, MCGs start forming and at the apical cell surfaces they fuse with the plasma membrane and their contents are discharged into the intercellular spaces at the upper one third of the epithelium. This barrier exists in the outermost 200 μm of the superficial layer.

Permeation studies have been performed using a number of very large molecular weight tracers, such as horseradish peroxidase²² and lanthanum nitrate²³. When applied to the outer surface of these tracers, they penetrate only through epithelium, these tracers penetrate only through outermost layer or two of cells. When applied to the submucosal surface, they permeate up to, but not into, the outermost cell layers of the epithelium. According to these results, it seems apparent that flattened surface cell layers present the main barrier to permeation, while the more isodiametric cell layers are relatively permeable. In both keratinized and non-keratinized epithelia, the limit of penetration coincided with the level where the MCGs could be seen adjacent to the superficial plasma membranes of the epithelial cells. Since the same result was obtained in both keratinized and non-keratinized epithelia, keratinization by itself is not expected to play a significant role in the barrier function²².

The components of the MCGs in keratinized and non-keratinized epithelia are different, however¹⁸. The MCGs of keratinized epithelium are composed of lamellar lipid stacks, whereas the non-keratinized epithelium contains MCGs that are non-lamellar. The MCG lipids of keratinized epithelia include sphingomyelin, glucosylceramides, ceramides, and other nonpolar lipids, however for non-keratinized epithelia, the major MCG lipid components are cholesterol esters, cholesterol, and glycosphingolipids¹⁸. Aside from the MCGs, the basement membrane may present some resistance to permeation as well, however the outer epithelium is still considered to be the rate limiting step to mucosal penetration. The structure of the basement membrane is not dense enough to exclude even relatively large molecules.

The epithelial barrier must be crossed by the drug molecules in order to reach their intended sites of action. The basic drug transport mechanism for buccal epithelium is the same as for other epithelia in the body. There are two major routes involved: transcellular (intracellular) route and paracellular (intercellular)²⁴ (Fig. 2). In general, for many of the drugs, permeation across the buccal epithelium is thought to be through paracellular route by passive diffusion. **Nevertheless and Kurosaki**²⁵ suggested the presence of a specialized transport system for cephadroxyll in the human buccal membrane.

Environment

The cells of the oral epithelia are surrounded by an intercellular ground substance, mucus, the principle components of which are complexes made up of proteins and carbohydrates. These complexes may be free of association or some may be attached to certain regions on the cell surfaces. This matrix may actually play a role in cell-cell adhesion, as well as acting as a lubricant, allowing cells to move relative to one another²⁶. Along the same lines, the




Figure 2. Routes of epithelial penetration: transcellular route and paracellular route; Adapted from reference²⁷

mucus is also believed to play a role in bioadhesion of mucoadhesive drug delivery systems²⁸.

In stratified squamous epithelia found elsewhere in the body, mucus is synthesized by specialized mucus secreting cells like the goblet cells, however in the oral mucosa; mucus is secreted by the major and minor salivary glands as part of saliva^{2, 26}. Up to 70% of the total mucin found in saliva is contributed by the minor salivary glands

^{2, 26}. At physiological pH the mucus network carries a negative charge (due to the sialic acid and sulfate residues) which may play a role in mucoadhesion. At this pH mucus can form a strongly cohesive gel structure that will bind to the epithelial cell surface as a gelatinous layer ¹⁶. Another feature of the environment of the oral cavity is the presence of saliva produced by the salivary glands. Saliva is the protective fluid for all tissues of the oral cavity. It protects the soft tissues from abrasion by rough materials and from chemicals. It allows for the continuous mineralisation of the tooth enamel after eruption and helps in remineralisation of the enamel in the early stages of dental caries ²⁹.

Saliva is an aqueous fluid with 1% organic and inorganic materials. The major determinant of the salivary composition is the flow rate which in turn depends upon three factors: the time of day, the type of stimulus, and the degree of stimulation ^{2, 26}. The salivary pH ranges from 5.5 to 7 depending on the flow rate. At high flow rates, the sodium and bicarbonate concentrations increase leading to an increase in the pH. The daily salivary volume is between 0.5 to 2 liters and it is this amount of fluid that is available to hydrate oral mucosal dosage forms. A main reason behind the selection of hydrophilic polymeric matrices as vehicles for oral transmucosal drug delivery systems is this water rich environment of the oral cavity.

Mechanisms Involved in Oral Mucosal Absorption

Passive Diffusion

JC. postulated that the major mechanism involved in the transfer of a drug across the oral mucosa is described by simple Fickian or passive diffusion of the unionized form of the drug in accordance with the pH-partition hypothesis ^{30, 31}. This was first demonstrated for buccal absorption with a series of amphetamines done by Beckett and coworkers ³². In this study, drug transport appeared to be a passive diffusion process since optical isomers of a drug were absorbed to the same extent; absorption was dependent on the concentration of un-ionized lipid-soluble form of the drug; and no difference in the percentage absorption of the drug at any given pH value was observed when the drug was given separately or as a mixture with other drugs. Since this initial finding, there have been many studies demonstrating the passive nature of transfer across the oral mucosa ³³⁻³⁹. Under these conditions of passive diffusion, the physicochemical properties of the membrane and the drug dictate the transport rate across the biological membrane ².

Carrier-Mediated Transport

Although passive diffusion is the major transport mechanism for drug permeation across the buccal mucosa, the absorption of certain nutrients from the oral cavity; done by Manning and coworkers; has been shown to involve carrier systems. The absorption of D-glucose and L-arabinose across the buccal mucosa was shown to be both saturable and stereospecific ⁴⁰. This indicated the presence of a carrier-mediated transport system for these sugars, since saturation and stereospecificity are not characteristics of a passive diffusion process. Additionally, the absorption of D-glucose, galactose, and 3-O-methyl-D-glucose was at least partly dependent on the presence of sodium ions, and the transport of D-glucose was inhibited by galactose and 3-O-methyl-D-glucose, suggesting that there was at least one common carrier system in the buccal mucosa ⁴⁰. Such a specialized mechanism for D-glucose transport was also observed by Kimura and coworkers in a cultured stratified cell layer of human oral mucosal cells ⁴¹. In another study by Kurosaki Y et al.; assessing the absorption of D-glucose at various sites in the oral cavity, absorption was found to be saturable only in the dorsum of the tongue, and these authors suggested that a specialized transport system for D-glucose existed only at this site ⁴². However, using Western blot analysis by Oyama and coworkers, various glucose transporters have been identified in cells of the buccal mucosa as well as the dorsum of the tongue and the buccal mucosa ⁴³. Therefore, greater clarification is required in this area.

In addition to sugars, the absorption studies ;done by Sadooghabasian and coworkers, and Evered and coworkers; of various vitamins, including L-ascorbic acid, nicotinic acid, and nicotinamide, have been shown to be dependent on the presence of sodium ions, indicating absorption from the oral cavity by carrier-mediated processes ^{44, 45}. When the absorption of thiamine was investigated by Evered and coworkers in vivo, absorption rates showed saturation at high concentrations of the vitamin ⁴⁶, giving further support to the finding that carrier-mediated processes are involved in the oral mucosal absorption of some nutrients.

Recent investigations; done by Utoguchi and coworkers; have also indicated the existence of an energy-dependent carrier-mediated monocarboxylic acid transporter system in primary cultures of rabbit and hamster oral mucosal cells, and in hamsters in vivo ^{47, 48}. Such carrier-mediated systems may be important in the transport of certain drugs, such as salicylic acid. Kurosaki and coworkers has also been shown that the absorption of cefadroxil, an aminoccephalosporin antibiotic, is absorbed in the human oral cavity via a specialized transport mechanism, since its absorption demonstrated saturation phenomena and was inhibited in the presence of another aminoccephalosporin, cephalixin ²⁵. Therefore, evidence is building to suggest that passive diffusion of compounds may not be the only mechanism by which compounds permeate the buccal mucosa.

There has also been a report by Brayton and coworkers regarding the active transport of antibacterial agents in oral mucosa. In a cell line derived from oral epithelium, the uptake of ciprofloxacin and minocycline was not only saturable and inhibited in the presence of other compounds, but the intracellular levels of both antibiotics were 8–40-fold higher than the extracellular levels as well, demonstrating an active transport process ⁴⁹. Whether the permeability of these compounds across the entire oral mucosa occurs via an active transport process, however, remains to be determined.

Estimating the ability of a drug to move through the oral mucosal membrane.

At present, there is no simple model capable of predicting buccal permeability of a wide range of small molecular drugs. This has led to the use of existing transdermal models such as the Potts–Guy (PG) model⁵⁰ for predicting buccal permeability due to the greater structural and biochemical proximity of buccal mucosa to skin than other tissues such as intestine. However, use of such models is inadequate as the permeation of ionized drug species is significant in the buccal mucosa and distribution coefficient (logD) was found to correlate better to the buccal permeability as opposed to logP that was proposed in the existing models. Drug permeability across a biological membrane depends on the properties of the barrier and permeant. Various structural and physicochemical parameters such as, size, charge, lipophilicity, and hydrogen-bonding capacity influence the permeability of a molecule across a membrane⁵¹.

Kokate, Amit and coworkers have designed a simple model to predict the buccal drug permeability, based on the work done by Mäkiä and coworkers⁵¹. A computational model to predict buccal permeability of drugs based on their structural and physicochemical properties was developed. Molecular volume, logD_{6.8}, number of hydrogen bond donors, and number of rotatable bonds were the most important parameters describing logK_p, briefly in the following equation:

$$\log K_p \left(\frac{cm}{s} \right) = -3.13(\pm 0.95) - 0.012(\pm 0.0051) \times MV - 0.617(\pm 0.170) \times HBD + 0.263(\pm 0.110) \times nRotB + 0.654(\pm 0.200) \times \log D_{6.8}$$

Where log K_p is the logarithm of the permeation coefficient, MV is the molecular volume, nRot is number of rotatable bonds, HBD is no. of hydrogen bond donors and log D_{6.8} is logarithm of distribution coefficient at pH 6.8, which corresponds to salivary pH.

Methods for assessment of oral mucosal permeation:

There have been a range of models used in the preclinical setting to assess the permeability of compounds across the buccal mucosa. While in vivo methods are often more appropriate in terms of assessing bioavailability via this route, in vitro and in situ methods have been instrumental for preclinical compound screening, elucidating mechanisms of transport across the buccal mucosa, and assessing the potential of chemical penetration enhancers for improvement of buccal transport.

In-vivo methods;

One of the most common in vivo methods used to assess the permeability of the buccal mucosa is the buccal absorption test of Beckett and Triggs³². In this test, a known volume of a drug solution is introduced into the oral cavity of a subject, who swirls it around for a specified period of time and then expels it. The subject then rinses his or her mouth with an aliquot of distilled water or buffer solution, and the expelled drug solution and rinse are combined and analyzed for drug content. The difference between the initial and final drug concentration in the solution is assumed to be the amount of drug taken up into the oral mucosa. The buccal absorption test of Beckett and Triggs has been modified slightly by various investigators.

To account for the production of saliva throughout the test, a correction factor was included by Dearden and Tomlinson⁵². Arbab and coworkers; Schurmann and coworkers, and Tucker; have added a marker compound into the swirling solution, such as phenol red or polyethylene glycol, to account for salivary dilution and accidental swallowing of the solution^{33, 53, 54}. Since kinetic profiles cannot be determined using the original buccal absorption test, Tucker modified the test by taking small samples of the swirled solution from the oral cavity every few minutes without removing the entire test solution⁵⁴. The major benefit of this is that the absorption kinetics of a drug may be studied in a single subject in a simple 15–20-min test.

Although the original and modified buccal absorption tests are easy to perform, do not require blood sampling, and allow for both the rate and the extent of drug loss from the oral cavity to be determined, there are some drawbacks to the method. One of the major disadvantages of this technique is that only the concentration of drug remaining in the oral cavity (swirling solution) is measured, and blood samples are not determined. The amount of drug which disappears from the swirling solution cannot be equated to the amount entering the systemic circulation, due to other factors including membrane storage, potential metabolism, and swallowing of the drug^{55, 56}. Since the solution is swirled around the oral cavity, absorption of compound may also occur through all surfaces within the oral cavity, and so the degree to which absorption occurs across a specific site (e.g., buccal and sublingual) remains unknown.

To overcome the limitation of nonspecific absorption across all surfaces of the oral cavity and to study regional variation in drug absorption, various absorption or perfusion cells have been designed (by Kurosaki and coworkers; Barsuhn and coworkers; Rathbone and coworkers; and Yamahara and coworkers); which can be clamped or attached to particular mucosae within the oral cavity of both animals and humans^{42, 57-64}. In this method, a drug solution is perfused through the cell and the drug absorption is again calculated by drug disappearance from the perfusate. Gandhi and coworkers stated that the major drawback with the perfusion cell technique is leakage and large intersubject variation²¹; however, these devices are a major advance in assessing the absorption characteristics of a particular region within the oral cavity, and would be most informative if the appearance of drug in the plasma was simultaneously monitored. In particular cases where plasma cannot be simultaneously assayed,

and there is information available relating the concentration of drug in saliva to the concentration in plasma, it is possible to collect saliva as a surrogate for plasma.

Following collection and analysis, an appropriate multiplication factor is incorporated for extrapolation to plasma concentrations. Such a method was recently used by Adrian and coworkers to assess the buccal absorption of nicotine in humans ⁶⁵. In this study, the disappearance of nicotine from the perfusion solution was used to determine the rate of nicotine absorption, and saliva was simultaneously collected directly from the parotid gland using a modified Carlson-Crittenden cup ⁶⁶ as a surrogate for plasma. While salivary concentrations increased as perfusion concentrations decreased, it is unknown whether this actually related to an increase in plasma concentrations. Consequently, it is important to determine whether there is a correlation between plasma concentrations and salivary concentrations, if this technique is to be successfully used as a predictor of systemic buccal absorption. However, as informative as such techniques may be, they may not be suitable in the preclinical setting, where high throughput permeability screening is required.

In-vitro Methods:

In vitro permeability models are often employed to determine the barrier nature of a particular biological tissue because the diffusion of drugs can be studied in an environment where variables such as temperature, pH, and osmolarity can be easily controlled ⁶⁷. When using an in vitro method to predict the absorption of compounds across the human buccal mucosa, an appropriate animal model must be chosen on the basis of its similarity in structure and permeability to the human buccal mucosa. Using the buccal mucosa of an appropriate animal model, in vitro permeability studies are then commonly conducted in diffusion cells. The advantage of in vitro diffusion cells is that the amount of drug that has actually diffused across the tissue can be determined over time, and thus the kinetics of tissue transport may be assessed. There are various diffusion cells that are used in the preclinical screening of compound permeability, including Franz-type diffusion cells, flow-through cells, and modified Ussing chambers.

Animals Models:

Because of the limited availability of the human buccal mucosa, it is often necessary to use freshly excised mucosa from an alternative animal species. If the role of in vitro studies is to assess the potential of the buccal mucosa as an alternative route for drug delivery in humans, then the buccal mucosa from the animal species chosen should be similar to the human buccal mucosa in terms of permeability, biochemistry, and morphology.

Aungst; and Siegel have used the oral mucosa of rats ^{68, 69}, while Coutelegros.; Garren; Kitano; Kurosaki; Sveinsson; Tsutsumi, and Ungphaiboon and coworkers have used the oral mucosa of hamsters ⁷⁰⁻⁷⁹, but these surfaces are keratinized, and so may not be an appropriate model of the non-keratinized human buccal mucosa.

Rabbit buccal mucosa is non-keratinized and has been used by Dowty; Gandhi; Nair; and Siegel; in many in vitro studies assessing the mucosal permeability of compounds ⁸⁰⁻⁸³; however, the small area of available non-keratinized tissue often limits its use ²⁰.

The buccal mucosa of dogs and monkeys is non-keratinized and therefore may be used by Squier; Addy; Mehta; Nielsen; and Siegel and coworkers; as a model for the human buccal mucosa; however, the epithelium of the mucosa in these animals is much thinner, and consequently, more permeable than that of humans ^{20, 84-87}.

The comparative permeability of tritiated water through various animal species and humans is shown in Table 1. In addition, the thickness of the buccal epithelium in each species is shown. Because of the physiologic, anatomic, nutritional, and metabolic similarities between humans and pigs ⁸⁸, Koh and Squier; suggested that the pig has become a widely used and important animal model for research on human disease. The buccal mucosa of pigs is non-keratinized and has a similar structure, morphology, and composition to the human buccal mucosa ^{19, 89, 90}. Additionally, as shown in Table 1, the thickness of the epithelia in human and porcine buccal mucosa is fairly similar. While structure and morphology are important determinants in the comparative process, the permeability characteristics of the model tissue must reflect the barrier nature of the human buccal mucosa.

Table 1. Epithelial thickness and permeability coefficient (P) for tritiated water through the buccal mucosa of different species together with epithelial thickness. ²⁰, data are $\pm$ SD

Species	$P \times 10^{-7}$ (cm/min)	Epithelial thickness (μ m)
Human	579 $\pm$ 122	580 $\pm$ 90
Pig	634 $\pm$ 60	772 $\pm$ 150
Monkey	1,025 $\pm$ 154	271 $\pm$ 50
Dog	1,045 $\pm$ 37	126 $\pm$ 20

The permeability of tritiated water through porcine buccal mucosa has been shown by Lesch and coworkers to be very similar to that of the human buccal mucosa ⁹¹, and more recently, no significant differences were observed by Nielsen and coworkers in the permeability of mannitol or testosterone through the porcine and the human buccal mucosa ⁸⁶. Because of the large amounts of pig oral mucosa available from slaughterhouses and

the similar structure and permeability to human tissue, most laboratories use porcine buccal mucosa when assessing mucosal permeability and the effect of various chemical penetration enhancers on mucosal drug delivery^{38, 92-115}. It is therefore recommended that preclinical evaluation of compound permeability across the buccal mucosa be performed with porcine buccal mucosa, as a result of its similar structure and permeability characteristics to that seen in the human buccal mucosa.

Issues Associated With In Vitro Permeability Assessment:

While the transport of compounds across the buccal mucosa may be assessed in a controlled environment with in vitro techniques, the ability to correlate the results obtained from the in vitro to the in vivo situation is often limited. It is thus necessary to consider the in vitro conditions and minimize, where possible, artifacts that may not be representative of the in vivo situation. This becomes particularly important when deciding on the thickness of the tissue to use in in vitro permeability experiments. When excising the buccal mucosa (as detailed in the appendix to this chapter), it is possible to use either full- thickness tissue (containing the buccal epithelium and underlying connective tissue) or buccal epithelium alone.

In studies in by Nicolazzo and coworkers using both full- thickness and epithelial tissue, the presence of connective tissue significantly reduced the buccal permeation of the hydrophilic marker caffeine and the lipophilic marker estradiol¹⁰².

However, Devries and coworkers observed that the difference in permeability was greater for estradiol than for caffeine, which may have been a result of the more hydrophilic nature of the connective tissue, which acts as a greater barrier for lipophilic compounds than for hydrophilic compounds⁹³. Given the blood vessels are located directly beneath the epithelial surface in vivo, Nicolazzo and coworkers suggested using epithelial tissue in place of full-thickness tissue, avoiding the artificial barrier created by connective tissue in the absence of circulation.

Integrity markers are often used in in vitro permeability experiments to ensure that the model membrane is intact and that the observed permeability profiles of model compounds are not a result of compromised tissue integrity. One common method of assessing tissue integrity is to include a nonabsorbable marker at the completion of a permeability experiment.

Nicolazzo and coworkers used the high molecular weight fluorescein isothiocyanate (FITC)-labeled dextran with a molecular weight of 20 kDa as a marker of tissue integrity¹⁰², on the basis that studies by Junginger and Hoogstraate and coworkers investigating the permeability of FITC-dextran have revealed that passage of such hydrophilic compounds through porcine buccal epithelium is restricted to permeants with a molecular weight less than 20 kDa^{15, 97, 98}.

Nicolazzo and coworkers have demonstrated that such a high molecular weight dextran appears only in the receptor chamber following intentional tissue damage, and this was accompanied by an increase in the permeability of caffeine¹⁰².

Wertz and Squier and coworkers stated that because of the possible effects of active and carrier-mediated processes and metabolic biotransformation, the issue of tissue viability is important for in vitro buccal mucosal experiments. The barrier nature of the buccal mucosa resides in the upper layers of the epithelium, where unlike in the stratum corneum, the cells contain a variety of functional organelles^{18, 20, 116, 117}, and so tissue viability may be an important component of the barrier function of the tissue.

Various methods have been employed to assess the viability of excised buccal mucosa, including measurement of biochemical markers, microscopic methods, and linearity of transport data¹⁷. Dowty and coworkers used a biochemical methods, including measurement of adenosine 5'-triphosphate (ATP) levels and utilization of glucose, provide information on the metabolic activity of the tissue, this does not necessarily relate to the barrier function of the tissue. In excised rabbit buccal mucosa, levels of ATP were measured and found to decline by 40% in 6 h, and this correlated well with transmission electron microscopic evaluation of the tissue (intact superficial cells)⁸⁰. In addition, the permeability of a model peptide was unaltered up to 6 h postmortem, but at 8 h, a significant change in permeability was observed⁸⁰. These investigators therefore claimed that excised rabbit buccal mucosa could be used for diffusion studies for ~6h.

Recently Shojaei and Zhang and coworkers have claimed that the tissue can be considered viable if the drug permeability does not change over the course of the experiment, and thus the actual permeability experiments themselves may provide insight into the viability of the tissue^{14, 67}. This method was employed in permeation experiments using porcine buccal mucosa, where the permeability of compounds was assessed in two consecutive permeability experiments to ensure the nature of the barrier was not compromised^{111, 118}.

While this demonstrates that the barrier nature of the tissue was unaltered between the permeation experiments, the tissue may have already undergone tissue death in the time between the excision and the commencement of the initial permeation experiment, and thus the permeability rate obtained in vitro may not be representative of the in vivo situation. Therefore, more studies assessing the dependence of the barrier nature of the buccal mucosa on tissue viability are required, especially since the role of specialized transport processes in oral mucosal permeability is becoming more appreciated.

Imbert and coworkers, assessed the viability of excised porcine buccal mucosa using histological evaluation and a 3-[4,5-di methylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) biochemical assay which has previously been used in assessing the viability of excised buccal mucosa and cornea^{119, 120}. Histological evaluation

of tissue done by Nicolazzo and coworkers demonstrated that the buccal epithelium appeared viable up to 9 h postmortem, and this was supported by the MTT biochemical assay, which indicated that viability was maintained for up to 12 h¹⁰². Therefore, it is recommended that all permeation experiments using porcine buccal mucosa be performed within 9–12 h of animal death. While there are limitations associated with the use of an in vitro permeability model for assessing the transport of compounds across the buccal mucosa, it can still be useful in assessing and comparing the permeability of compounds under different conditions, such as pH, temperature, and osmolarity, which provide valuable information on the mechanisms involved in drug transport. Additionally, the preliminary effects of potential chemical penetration enhancers or formulation excipients may be assessed, and these may provide a substantial rationale for subsequently assessing the effect of these agents in man.

Buccal Cell Cultures

The use of buccal cell cultures for assessing the permeability of the buccal mucosa has attracted recent attention. In order to culture buccal epithelial cells, the cells must be harvested from an appropriate source and cultured under specific conditions using an appropriate growth medium, temperature, and humidity⁵⁶. Cell cultures have been successfully grown by Tavakolisaberi and coworkers from hamster cheek pouch. These cultured cells, however, did not differentiate to form a complete keratinized surface as seen in the normal hamster cheek pouch, and they consequently displayed a greater permeability to compounds when compared with keratinized hamster cheek pouch mucosa¹²¹. Therefore, the cultured hamster cheek cells more closely mimicked the human buccal mucosa due to their lack of keratinization, and so this may be an appropriate model for predicting permeability through the human buccal mucosa.

Another cell culture model which has been proposed as a model of the human buccal epithelium is the TR146 cell line by Nielsen and coworkers^{86, 122-125}. Rupniak and coworkers stated that the TR146 cells originate from a human buccal carcinoma¹²⁶, and when cultured, Jacobsen and coworkers showed that they form an epithelium resembling that of the buccal mucosa¹²³, with the appropriate differentiation patterns seen in human non-keratinized epithelium¹²⁷. However, Nielsen and coworkers proved that the TR146 cell culture model has less of a barrier nature when compared to human and porcine buccal epithelium, as demonstrated by a significantly greater permeability to tritiated water, mannitol, testosterone, dextrans, and nicotine^{86, 124, 128, 129}, and this may be due to the cancerous nature of the original cells.

Recently, a cell culture derived from biopsies of healthy human buccal mucosa has been developed by Selvaratnam and coworkers with remarkably similar morphology, membrane-coating granule structure and appearance, and lipid composition to intact buccal tissue¹³⁰. The barrier nature of this cell culture model is similar to intact buccal mucosa, and so this cell culture may be an alternative model to the TR146 cell culture. With the development of tissue culture techniques, it is anticipated that various cell culture models may be developed with similar morphological and barrier properties to normal intact buccal mucosa. Such models may be very useful in assessing the buccal permeability and metabolism of many compounds.

Buccal Permeation Enhancement:

To overcome the permeability issue of the buccal mucosa, there is a simple approach to include chemical compounds into the buccal delivery systems that promote the penetration of the active drug ingredients into the across it. So, these compounds are termed “buccal penetration enhancers or promoters”.

Aungst stated that the chemicals used as penetration enhancers ideally should be safe and non-toxic, pharmacologically and chemically inert, non-irritant, and non-allergenic¹³¹. In addition, the tissue should revert to its normal integrity and barrier properties upon removal of the chemical.

Mechanisms of action of buccal penetration enhancers:

Ganem-Quintanar and coworkers stated that mechanisms by which penetration enhancers are thought to improve mucosal absorption include the following¹³²:

- (i) Changing mucus rheology: Mucus covers the respiratory, gastrointestinal and genitourinary tracts, and forms a viscoelastic layer of varying thickness which affects drug absorption¹³². In the mouth, it is covered by a layer of saliva. There is evidence that, for certain drugs, saliva can hinder absorption, but usually it is insignificant compared to the other barriers during passage through the oral mucosa². Therefore, saliva may have only a transient contribution to the oral barrier function, for example, decreasing the initial passage of water through the buccal epithelium¹³³.
- (ii) Increasing the fluidity of membrane lipid bilayers: As the intercellular pathway is the most generally accepted route for drug absorption^{56, 116, 117, 134, 135} the disruption of inter-cellular lipid packing, by interaction with either lipid or protein components, is thought to increase permeability. Biophysical techniques, e.g. differential scanning calorimetry (DSC) and infrared spectroscopy (IR), have demonstrated that, there is indeed, a correlation between increased lipid fluidity and enhanced membrane permeability. Varying degrees of insult may occur in tissues that are in intimate contact with the enhancer¹³², therefore, a transient increase in the fluidity of the intercellular lipids may be thought of as a relatively nontoxic effect, whereas extraction of the intercellular lipids or denaturation of cellular proteins may be viewed as being somewhat more drastic. Therefore, an important consideration is to ensure that the effect of the enhancer on membrane permeability is reversible¹³⁶.

- (iii) Affecting the components involved in the formation of intercellular junctions: This could be particularly important in the case of intestinal membranes, where the barriers to paracellular diffusion of molecules and ions are the tight junctions or 'zona occludens'. Although in oral mucosa tight junctions are almost absent, desmosomes, which are thought confer added structural integrity, occupy $\approx 47\%$ of the intercellular space of the palatal stratum corneum and a further $\approx 10\%$ is occupied by saccules¹³⁷. This suggests that disruption of these structures may provide a permeability pathway through the oral stratum corneum, but this has not been entirely confirmed^{137, 138}.
- (iv) Overcoming the enzymatic barrier: Protease inhibitors for endo- and exo-peptidases are potential penetration enhancers. Although various peptidases and proteases are present within the oral mucosa, and it is possible that metabolism may act as an enzymatic barrier, the intercellular pathway is thought to be deficient in proteolytic activity^{132, 136}. However, changes in membrane fluidity induced by penetration enhancers may indirectly alter enzymatic activity¹³².
- (v) Increasing the thermodynamic activity of drugs: This may be affected by the vehicle composition, which will influence drug solubility^{139, 140} and also by ion-pair formation between the enhancer and the drug^{70, 141}.

Cyclodextrins as penetration Enhancer:

Senel and Hincal showed that cyclodextrins have been classified as a new class of penetration enhancers.¹⁴² Irie and coworkers showed that cyclodextrins can enhance drug permeation by increasing drug availability and stability at the surface of the biological barriers¹⁴³

Mucoadhesion and Mucoadhesive Polymers used in Oral Mucosal Delivery:

Bio adhesion is defined as the state in which two bodies' one or both of adherents are of a biological nature and are held together for extended periods of time by interfacial forces. A bio adhesive can therefore be defined as a substance, which has an ability to interact with biological materials, and is capable of being retained on the biological substrate for a period of time. One distinctive feature of bioadhesion is that adhesion almost always occurs in the presence of water.

Mucus is a gel like structure that covers the oral cavity. Mucus is secreted by the goblet cells lining the epithelia or by the special exocrine glands with mucus cells acini^{144, 145}. Any bioadhesive material must first interact with the mucus for bioadhesion. Thus, mucus serves as a link between the bioadhesive material and the membrane. The composition and thickness of the mucus layer vary with location, sex, and state of health¹⁴⁵.

Mucus is a hydrated glycoprotein network. These glycoproteins consist of a protein core with oligosaccharide pendant chains most of them end with sialic acid or sulfonic acid^{146, 147}, or L-fucose¹⁴⁸. These oligosaccharide chains are covalently attached to the hydroxy amino acids, serine, and threonine along the polypeptide backbone¹⁴⁹. Figure 2 shows a schematic representation of the glycoprotein mucin. Each of the side chains composes anywhere from 2-20 sugars in length and terminates in sialic or fucose. About 25% of the polypeptide chain lacks sugars and is referred to as "naked" protein region, which is especially prone to enzymatic cleavage¹⁵⁰. The remaining 75% of the backbone is heavily glycosylated. The terminal sialic acid groups have a pKa of 2.6¹⁴⁹. At physiological pH, the mucus network is negatively charged because of the presence of sialic acid and sulfate residues, which are responsible for bioadhesion.

Mechanisms of adhesions:

The mechanisms of bioadhesion are not completely clear. To develop a good adhesive system, it is important to understand and elaborate the forces responsible for adhesive bond formation. Two steps have been described for an adhesive bond formation: 1. intimate contact of the polymer by wetting and swelling. 2. interpenetration and diffusion¹⁵¹. Bioadhesive bonds formed can be either mechanical or chemical in nature.

Mechanical or Physical bonds: These bonds form as a result of physical entanglement between the polymer and the mucin chains and interpenetration of the mucin strands into the porous polymer. The rate of bond formation depends on the rate of interpenetration of the polymer chains and the mucin strands, which in turn depends on the diffusion coefficients, and flexibility of the chains. The bonding strength of the adhesive bond is directly proportional to the depth of penetration of the polymer and mucin chains¹⁵².

Chemical Bonds: These may include strong primary bonds (i.e., covalent bonds and ionic bonds), van der Waals interactions, and hydrogen bonds. Mucoadhesive delivery system with primary bonds as the driving force for mucoadhesion is not sought due to irreversible damage of tissue/mucosa surface. Researchers have focused on developing mucoadhesive systems that bond through van der Waals interactions and hydrogen bonding. Although these forces are weak, strong bioadhesion can be produced through numerous interaction sites. Therefore, polymers with high molecular weights and greater concentrations of polar groups (such as -COOH, and -OH) tend to develop more intense mucoadhesive bonds¹⁵².

Theories of bioadhesion:

Several theories of bioadhesion have been proposed for the adhesiveness of the polymer with the mucus. These bioadhesion theories include adsorption, wetting, electronic, diffusion, and fracture.

Adsorption theory: This theory states that the adhesive bond is formed after an initial contact between the polymer and the substrate. Van der Waals interactions, hydrogen bonds, and other related weak interaction bonds are thought to play an important role. This theory was best explained by Kinloch and Huntsberger [32].

Wetting theory: This theory explains bioadhesion based on the ability of the polymer or the mucus to spread and develop an intimate contact with each other. Work of adhesion, which is the energy required to break the unlike molecules can be expressed in terms of surface and interfacial tension (γ) defined as the energy per cm^2 . Work of adhesion is given by Dupre's Equation [33].

$$W_a = \gamma_m + \gamma_p - \gamma_{mp} \quad \text{Eq. 2}$$

Where, the subscripts m and p refers to mucosa and bioadhesive polymer respectively. The work of cohesion, required to separate the two layers of the spreading liquid so that one of the layer flows on the other layer. Work of cohesion is given by

$$W_c = 2\gamma_m \text{ or } 2\gamma_p \quad \text{Eq. 3}$$

Spreading occurs if the work of adhesion is greater than the work of cohesion. The term ($W_a - W_c$) is known as the spreading coefficient (S). For the bioadhesive polymer p to spread on the mucous membrane m, the spreading coefficient S is given by

$$S_{p/m} = \gamma_m - \gamma_{mp} + \gamma_p \quad \text{Eq. 4}$$

if $S_{p/m}$ is positive, the bioadhesive polymer will adhere to the mucous membrane. For a liquid adhering to the mucous membrane m, the contact angle is given by

$$\cos \theta = \left(\gamma_m - \left(\gamma_{mp} / \gamma_p \right) \right) \quad \text{Eq. 5}$$

Mutual spreading of the mutual systems i.e., pig intestinal mucosa and bioadhesive polymer, is essential for the mucoadhesion^{151, 153}.

Diffusion theory: This theory states that the intermingling and interpenetration of the mucus chains and the bioadhesive polymer produces a semi-permanent bond¹⁵⁴. The bioadhesive polymer and the mucus glycoproteins come in close contact with each other. The bond strength depends on the depth of the penetration of these polymer chains. The following equation can be used to estimate the depth of the penetration:

$$L = (tD_b)^{0.5} \quad \text{Eq. 6}$$

Where t is the contact time and D_b is the diffusion coefficient of the biomaterial in mucus. The depth of penetration (L) depends upon the diffusion coefficient, time of contact and other experimental variables¹⁵⁵.

Electronic theory: According to this theory, electron transfer occurs on contact of an adhesive polymer with a mucus glycoprotein network due to their differences in electronic structures.

Fracture theory: This is the most useful theory for the study of bioadhesion through tensile experiments. This theory is related to the forces required for the separation of the two layers after adhesion. The fracture strength σ , which is the adhesive strength, is given by

$$\sigma = \left(E\varepsilon / l \right)^{0.5} \quad \text{Eq. 7}$$

Where E is the fracture energy, ε is the Young's modulus, and l is the critical crack length¹⁵⁶.

From a bioadhesive delivery point of view, understanding the mechanism of bioadhesion, theories, which best explain these phenomena, are a combination of wetting, diffusion, and electronic theory, although other mechanisms may be operative for a given system.

Salamat-Miller and coworkers wrote a full comprehensive review about the mucoadhesion and the use of mucoadhesive polymers in the buccal delivery¹⁵⁷.

Conclusion:

The study of oral mucosal absorption and its application in drug delivery systems has gained significant attention due to its potential to improve the bioavailability of drugs and reduce the side effects associated with systemic administration. The review has highlighted the importance of saliva in maintaining the health of the oral tissues and facilitating drug delivery. The mechanisms of oral mucosal absorption, particularly passive diffusion, have been discussed, and the use of hydrophilic polymeric matrices as vehicles for oral transmucosal drug delivery systems has been emphasized. The review has also explored the methods used to assess oral mucosal permeation, including both in vivo and in vitro approaches. In vivo methods, such as the buccal absorption test, allow for the bioavailability of drugs via this route to be determined, while in vitro methods, such as diffusion cells, enable the kinetics of tissue transport to be assessed. The use of appropriate animal models in in vitro permeability studies has been emphasized to ensure that the model membrane is intact and that the observed permeability profiles of model compounds are not a result of compromised tissue integrity. The review has also addressed the challenges and limitations associated with oral mucosal drug delivery, such as the difficulty in studying regional variation in drug absorption and the limitations of in vitro permeability models in predicting in vivo situations. To overcome these limitations, various absorption or perfusion cells have been designed to study regional variation in drug absorption. Future studies should focus on the buccal routes and permeability, as these areas have significant potential for improving drug delivery systems. The correlation between plasma concentrations and salivary concentrations should be further investigated to determine the validity of using saliva as a surrogate for plasma in assessing systemic buccal absorption. Additionally, high-throughput permeability screening is required in the preclinical setting, and in vitro permeability models can be useful in assessing and comparing the permeability of compounds under different conditions, providing valuable information on the mechanisms involved in drug transport.

References

1. Aungst, B.J., *Intestinal Permeation Enhancers*. Journal of Pharmaceutical Sciences, 2000. **89**(4): p. 429-442.
2. Rathbone, M.J., Drummond, B.K., and Tucker, I.G., *The Oral Cavity as a Site for Systemic Drug-Delivery*. Advanced Drug Delivery Reviews, 1994. **13**(1-2): p. 1-22.
3. Goodman, C.H. and Squier, C.A., *Blood-Flow in the Oral-Mucosa of Normal and Atherosclerotic Rhesus-Monkeys*. Journal of Oral Pathology & Medicine, 1988. **17**(1): p. 34-38.
4. Squier, C.A., *The Permeability of Oral Mucosa*. Critical Reviews in Oral Biology and Medicine, 1991. **2**(1): p. 13-32.
5. Sudhakar, Y., Kuotsu, K., and Bandyopadhyay, A.K., *Buccal bioadhesive drug delivery - A promising option for orally less efficient drugs*. Journal of Controlled Release, 2006. **114**(1): p. 15-40.
6. Gale, W.R., Lonsdale, H.K., and Nacht, S., *In vitro Permeability Of Skin and Buccal Mucosa to Selected Drugs and Tritiated-Water*. Journal of Investigative Dermatology, 1976. **67**(6): p. 713-717.
7. Squier, C.A. and Wertz, P.W., *Permeability and The Pathphysiology of Oral-Mucosa*. Advanced Drug Delivery Reviews, 1993. **12**(1-2): p. 13-24.
8. Sobrero, A., Comptes Rendus Hebdomadaires des Sciences. de l'Academie des Sciences, 1847. **24**: p. 247-248.
9. Walton, R.P.L., C. F. , *Absorption Of Drugs Through The Oral Mucosa*. J. Pharmacol. Exp. Ther., 1935. **54**(1): p. 61-76.
10. Walton, R.P., *Sublingual Administration Of Drugs*. J Am Med Assoc. , 1944. **124**(3): p. 138-143.
11. Katz, M. and Barr, M., *A Study Of Sublingual Absorption .1. Several Factors Influencing The Rate Of Absorption*. Journal of the American Pharmaceutical Association, 1955. **44**(7): p. 419-423.
12. Gibaldi, M. and Kanig, J.L., *Absorption Of Drugs Through The Oral Mucosa*. J Oral Ther Pharmacol, 1965. **31**: p. 440-50.
13. Squier, C.A. and Johnson, N.W., *Permeability of Oral-Mucosa*. British Medical Bulletin, 1975. **31**(2): p. 169-&.
14. Shojaei, A.H., *Buccal Mucosa as a Route for Systemic Drug Delivery: A Review*. J Pharm Pharm Sci, 1998. **1**(1): p. 15-30.
15. Junginger, H.E., Hoogstraate, J.A., and Verhoef, J.C., *Recent Advances in Buccal Drug Delivery and Absorption - In Vitro and In Vivo Studies*. Journal of Controlled Release, 1999. **62**(1-2): p. 149-159.
16. Gandhi, R.B. and Robinson, J.R., *Bioadhesion in Drug Delivery*. Indian Journal of Pharmaceutical Sciences, 1988. **50**(3): p. 145-152.
17. Harris, D. and Robinson, J.R., *Drug Delivery Via The Mucous-Membranes of The Oral Cavity*. Journal of Pharmaceutical Sciences, 1992. **81**(1): p. 1-10.
18. Wertz, P.W. and Squier, C.A., *Cellular and Molecular-Basis of Barrier Function in Oral Epithelia*. Critical Reviews in Therapeutic Drug Carrier Systems, 1991. **8**(3): p. 237-269.
19. Squier, C.A., Cox, P., and Wertz, P.W., *Lipid-Content and Water Permeability of Skin and Oral-Mucosa*. Journal of Investigative Dermatology, 1991. **96**(1): p. 123-126.
20. Squier, C.A.a.W., P.W. , *Structure and Function of The Oral Mucosa and Implications for Drug Delivery*, in *Oral Mucosal Drug Delivery*, M.J. Rathbone, Editor. 1996, Marcel Dekker, Inc., New York: New York. p. 1-26.
21. Gandhi, R.B. and Robinson, J.R., *Oral Cavity as a Site for Bioadhesive Drug-Delivery*. Advanced Drug Delivery Reviews, 1994. **13**(1-2): p. 43-74.
22. Squier, C.A. and Hall, B.K., *The Permeability Of Mammalian Nonkeratinized Oral Epithelia to Horseradish-Peroxidase Applied Invivo and Invitro*. Archives of Oral Biology, 1984. **29**(1): p. 45-50.
23. Hill, M.W. and Squier, C.A., *Permeability Of Rat Palatal Mucosa Maintained in Organ-Culture*. Journal of Anatomy, 1979. **128**(JAN): p. 169-178.
24. L. Narawane, V.H.L.L., *Absorption Barriers.*, in *Drug Absorption Enhancement. Concepts, Possibilities, Limitations and Trends*, A.G.d.B. (Ed.), Editor. 1994, Harwood Academic: Switzerland. p. 1-66.
25. Kurosaki, Y., Nishimura, H., Terao, K., et al., *Existence of a Specialized Absorption Mechanism for Cefadroxil, An Aminocephalosporin Antibiotic, in The Human Oral Cavity*. International Journal of Pharmaceutics, 1992. **82**(3): p. 165-169.
26. Tabak, L.A., Levine, M.J., Mandel, I.D., et al., *Role Of Salivary Mucins in The Protection Of The Oral Cavity*. Journal of Oral Pathology & Medicine, 1982. **11**(1): p. 1-17.
27. Merkle, H.P. and Wolany, G., *Buccal Delivery for Peptide Drugs*. Journal of Controlled Release, 1992. **21**(1-3): p. 155-164.
28. Peppas, N.A. and Buri, P.A., *Surface Interfacial and Molecular Aspects Of Polymer Bioadhesion on Soft Tissues*. Journal of Controlled Release, 1985. **2**: p. 257-276.
29. Edgar, W.M., *Saliva - Its Secretion, Composition and Functions*. British Dental Journal, 1992. **172**(8): p. 305-312.

30. JC, M., *Buccal Absorption of Drugs*, in *Encyclopedia of Pharmaceutical Technology*, B.J. Swarbrick J, Editor. 1990, Marcel Dekker: New York. p. 189–211.
31. Siegel IA, H.S., Stambaugh R, *Permeability Of the Oral Mucosa*, in *Current Concepts of the Histology of Oral Mucosa*, M.J. Squier CA, Editor. 1971, Thomas: Springfield. p. 274–286.
32. Beckett, A.H. and Triggs, E.J., *Buccal Absorption Of basic Drugs and its Application as an In vivo Model Of Passive Drug Transfer Through Lipid Membranes*. J Pharm Pharmacol, 1967. **19**: p. Suppl:31S-41S.
33. Arbab, A.G. and Turner, P., *Influence Of pH On Absorption Of Thymoxamine Through Buccal Mucosa in Man*. British Journal of Pharmacology, 1971. **43**(2): p. P479-&.
34. Beckett, A.H. and Moffat, A.C., *Correlation Of Partition Coefficient In n-Heptane-Aqueous Systems With Buccal Absorption Data For A Series Of Amines and Acids*. Journal of Pharmacy and Pharmacology, 1969. **S 21**: p. S144-&.
35. Beckett Ah Boyes, R.N. and Triggs, E.J., *Kinetics Of Buccal Absorption Of Amphetamines*. J Pharm Pharmacol, 1968. **20**(2): p. 92-7.
36. Bergman, S., Siegel, I.A., and Ciancio, S., *Absorption Of Carbon-14 Labeled Lidocaine Through Oral Mucosa*. Journal of Dental Research, 1968. **47**(6P2): p. 1184-&.
37. Bergman, S., Kane, D., Siegel, I.A., et al., *In Vitro and In Situ Transfer Of Local Anaesthetics Across Oral Mucosa*. Archives of Oral Biology, 1969. **14**(1): p. 35-&.
38. Chen, L.L.H., Chetty, D.J., and Chien, Y.W., *A Mechanistic Analysis to Characterize Oramucosal Permeation Properties*. International Journal of Pharmaceutics, 1999. **184**(1): p. 63-72.
39. Chetty, D.J., Chen, L.L.H., and Chien, Y.W., *Characterization of Captopril Sublingual Permeation: Determination of Preferred Routes and Mechanisms*. Journal of Pharmaceutical Sciences, 2001. **90**(11): p. 1868-1877.
40. Manning, A.S. and Evered, D.F., *Absorption Of Sugars From Human Buccal Cavity*. Clinical Science and Molecular Medicine, 1976. **51**(2): p. 127-132.
41. Kimura, T., Yamano, H., Tanaka, A., et al., *Transport of D-glucose Across Cultured Stratified Cell Layer of Human Oral Mucosal Cells*. Journal of Pharmacy and Pharmacology, 2002. **54**(2): p. 213-219.
42. Kurosaki, Y., Yano, K., and Kimura, T., *Perfusion Cells for Studying Regional Variation in Oral Mucosal Permeability in Humans. 2. A Specialized Transport Mechanism in D-Glucose Absorption Exists in Dorsum of Tongue*. Journal of Pharmaceutical Sciences, 1998. **87**(5): p. 613-615.
43. Oyama, Y., Yamano, H., Ohkuma, A., et al., *Carrier-mediated Transport Systems for Glucose in Mucosal Cells of The Human Oral Cavity*. Journal of Pharmaceutical Sciences, 1999. **88**(8): p. 830-834.
44. Sadooghabasian, F. and Evered, D.F., *Absorption Of Vitamin-C From The Human Buccal Cavity*. British Journal of Nutrition, 1979. **42**(1): p. 15-20.
45. Evered, D.F., Sadooghabasian, F., and Patel, P.D., *Absorption Of Nicotinic-Acid and Nicotinamide Across Human Buccal Mucosa In vivo*. Life Sciences, 1980. **27**(18): p. 1649-1651.
46. Evered, D.F. and Mallett, C., *Thiamone-Absorption Across Human Buccal Mucosa In vivo*. Life Sciences, 1983. **32**(12): p. 1355-1358.
47. Utoguchi, N., Watanabe, Y., Takase, Y., et al., *Carrier-mediated Absorption of Salicylic Acid from Hamster Cheek Pouch Mucosa*. Journal of Pharmaceutical Sciences, 1999. **88**(1): p. 142-146.
48. Utoguchi, N., Watanabe, Y., Suzuki, T., et al., *Carrier-mediated Transport of Monocarboxylic Acids in Primary Cultured Epithelial Cells from Rabbit Oral Mucosa*. Pharmaceutical Research, 1997. **14**(3): p. 320-324.
49. Brayton, J.J., Yang, Q., Nakkula, R.J., et al., *An In Vitro Model of Ciprofloxacin and Minocycline Transport by Oral Epithelial Cells*. Journal of Periodontology, 2002. **73**(11): p. 1267-1272.
50. Potts, R.O. and Guy, R.H., *Predicting Skin Permeability*. Pharmaceutical Research, 1992. **9**(5): p. 663-669.
51. Mälkiä, A., Murtomäki, L., Urtti, A., et al., *Drug Permeation in Biomembranes: In Vitro and In Silico Prediction and Influence of Physicochemical Properties*. European Journal of Pharmaceutical Sciences, 2004. **23**(1): p. 13-47.
52. Dearden, J.C. and Tomlinso, E., *Correction For Effect Of Dilution on Diffusion Through a Membrane*. Journal of Pharmaceutical Sciences, 1971. **60**(8): p. 1278-&.
53. Schurmann, W. and Turner, P., *Membrane Model Of Human Oral-Mucosa As Derived From Buccal Absorption Performance and Physicochemical Properties Of Beta-Blocking Drugs Atenolol and Propranolol*. Journal of Pharmacy and Pharmacology, 1978. **30**(3): p. 137-147.
54. Tucker, I.G., *A Method to Study The Kinetics Of Oral Mucosal Drug Absorption From Solutions*. Journal of Pharmacy and Pharmacology, 1988. **40**(10): p. 679-683.
55. Ho, N.F.H., *Biophysical Kinetic Modelling of Buccal Absorption*. Advanced Drug Delivery Reviews, 1993. **12**(1-2): p. 61-97.
56. Hoogstraate, A.J. and Bodde, H.E., *Methods for Assessing the Buccal Mucosa as a Route of Drug-Delivery*. Advanced Drug Delivery Reviews, 1993. **12**(1-2): p. 99-125.
57. Barsuhn, C.L., Olanoff, L.S., Gleason, D.D., et al., *Human Buccal Absorption of Flubiprofen*. Clinical Pharmacology & Therapeutics, 1988. **44**(2): p. 225-231.

58. Kurosaki, Y., Yano, K., and Kimura, T., *Perfusion Cells for Studying Regional Variation in Oral-Mucosal Permeability in Humans .1. Kinetic Aspects in Oral-Mucosal Absorption of Alkylparabens*. Pharmaceutical Research, 1997. **14**(9): p. 1241-1245.
59. Oh, C.K. and Ritschel, W.A., *Biopharmaceutic Aspects of Buccal Absorption of Insulin*. Methods and Findings in Experimental and Clinical Pharmacology, 1990. **12**(3): p. 205-212.
60. Rathbone, M.J., *Human Buccal Absorption .1. A Method for Estimating The Transfer Kinetics of Drugs Across The Human Buccal Membrane*. International Journal of Pharmaceutics, 1991. **69**(2): p. 103-108.
61. Rathbone, M.J., *Human Buccal Absorption .2. A Comparative-Study of The Buccal Absorption of Some Parahydroxybenzoic Acid-Derivatives Using The Buccal Absorption Test and a Buccal Perfusion Cell*. International Journal of Pharmaceutics, 1991. **74**(2-3): p. 189-194.
62. Yamahara, H., Suzuki, T., Mizobe, M., et al., *Insitu Perfusion System for Oral Mucosal Absorption in Dogs*. Journal of Pharmaceutical Sciences, 1990. **79**(11): p. 963-967.
63. Zhang, J., Niu, S., McJames, S., et al., *Buccal Absorption of Insulin in an In-vivo Dog Model Evidence of Mucosal Storage*. Pharmaceutical Research 1991. **8**(10 SUPPL): p. S156.
64. Zhang, J., Niu, S., Maland, L.J., et al., *Buccal Permeability of Oral Transmucosal Fentanyl Citrate OTFC in a Dog Model*. Pharmaceutical Research (New York), 1991. **8**(10 SUPPL): p. S155.
65. Adrian, C.L., Olin, H.B.D., Dalhoff, K., et al., *In Vivo Human Buccal Permeability of Nicotine*. International Journal of Pharmaceutics, 2006. **311**(1-2): p. 196-202.
66. Bardow, A., Madsen, J., and Nauntofte, B., *The Bicarbonate Concentration in Human Saliva Does not Exceed The Plasma Level Under Normal Physiological Conditions*. Clin Oral Investig, 2000. **4**(4): p. 245-53.
67. Zhang H, R.J., *In Vitro Methods for Measuring Permeability of The Oral Mucosa*, in *Oral Mucosal Drug Delivery*, R. MJ, Editor. 1996, Marcel Dekker: New York. p. 85–100.
68. Aungst, B.J., Rogers, N.J., and Shefter, E., *Comparison of Nasal, Rectal, Buccal, Sublingual and Intramuscular Insulin Efficacy and The Effects of A Bile-Salt Absorption Promoter*. Journal of Pharmacology and Experimental Therapeutics, 1988. **244**(1): p. 23-27.
69. Siegel, I.A. and Gordon, H.P., *Surfactant-Induced Increases Of Permeability Of Rat Oral-Mucosa to Non-electrolytes In vivo*. Archives of Oral Biology, 1985. **30**(1): p. 43-47.
70. Coutelegros, A., Maitani, Y., Veillard, M., et al., *Combined Effects of pH, Cosolvents and Penetration Enhancers on The Invitro Buccal Absorption of Propranolol Through Excised Hamster-Cheek Pouch*. International Journal of Pharmaceutics, 1992. **84**(2): p. 117-128.
71. Garren, K.W. and Repta, A.J., *Buccal Drug Absorption .2-Invitro Diffusion Across The Hamster-Cheek Pouch*. Journal of Pharmaceutical Sciences, 1989. **78**(2): p. 160-164.
72. Kitano, M., Maitani, Y., Takayama, K., et al., *Buccal Absorption Through Golden Hamster Cheek Pouch In Vitro and In Vivo of 17 beta-Estradiol from Hydrogels Containing Three Types of Absorption Enhancers*. International Journal of Pharmaceutics, 1998. **174**(1-2): p. 19-28.
73. Kurosaki, Y., Hisaichi, S., Nakayama, T., et al., *Enhancing Effect of 1-Dodecylazacycloheptan-2-one (Azone) on The Absorption of Salicylic Acid from Keratinized Oral-Mucosa and The Duration of Enhancement In vivo*. International Journal of Pharmaceutics, 1989. **51**(1): p. 47-54.
74. Kurosaki, Y., Hisaichi, S., Hamada, C., et al., *Effects of Surfactants on The Absorption Of Salicylic-Acid From Hamster-Cheek Pouch as A Model of Keratinized Oral-Mucosa*. International Journal of Pharmaceutics, 1988. **47**(1-3): p. 13-19.
75. Kurosaki, Y., Takatori, T., Kitayama, M., et al., *Application of Propranolol to The Keratinized Oral-Mucosa - Avoidance of 1st-Pass Elimination and The Use of 1-Dodecylazacycloheptan-2-one (Azone) as an Absorption Enhancer of Bioadhesive Film-Dosage Form*. Journal of Pharmacobio-Dynamics, 1988. **11**(12): p. 824-832.
76. Kurosaki, Y., Hisaichi, S., Hong, L.Z., et al., *Enhanced Permeability of Keratinized Oral-Mucosa to Salicylic-Acid with 1-Dodecylazacycloheptan-2-one (Azone) - Invitro Studies in Hamster-Cheek Pouch*. International Journal of Pharmaceutics, 1989. **49**(1): p. 47-55.
77. Sveinsson, S.J. and Mezei, M., *Invitro Oral Mucosal Absorption of Liposomal Triamcinolone Acetonide*. Pharmaceutical Research, 1992. **9**(10): p. 1359-1361.
78. Tsutsumi, K., Obata, Y., Takayama, K., et al., *Permeation of Several Drugs Through Keratinized Epithelial-free Membrane of Hamster Cheek Pouch*. International Journal of Pharmaceutics, 1999. **177**(1): p. 7-14.
79. Ungphaiboon, S. and Maitani, Y., *In Vitro Permeation Studies of Triamcinolone Acetonide Mouthwashes*. International Journal of Pharmaceutics, 2001. **220**(1-2): p. 111-117.
80. Dowty, M.E., Knuth, K.E., Irons, B.K., et al., *Transport of Thyrotropin-Releasing-Hormone in Rabbit Buccal Mucosa In vitro*. Pharmaceutical Research, 1992. **9**(9): p. 1113-1122.
81. Gandhi, R. and Robinson, J., *Mechnisms of Penetration Enhancement for Transbuccal Delivery of Salicylic-Acid*. International Journal of Pharmaceutics, 1992. **85**(1-3): p. 129-140.
82. Nair, M. and Chien, Y.W., *Buccal Delivery of Progestational Steroids .1. Characterization of Barrier Properties and Effect of Penetrant Hydrophilicity*. International Journal of Pharmaceutics, 1993. **89**(1): p. 41-49.

83. Siegel, I.A. and Gordon, H.P., *Surfactant-Induced Alterations of Permeability of Rabbit Oral-Mucosa In Vitro*. Experimental and Molecular Pathology, 1986. **44**(2): p. 132-137.
84. Addy, M., *The Oral Mucosal Absorption and Tissue Distribution Of Triamcinolone Acetonide in The Dog Studied By Autoradiography*. Archives of Oral Biology, 1980. **25**(11-1): p. 809-817.
85. Mehta, M., Kemppainen, B.W., and Stafford, R.G., *In Vitro Penetration of Tritium-Labeled Water (THO) and H-3 PBTX-3 (A Red Tide Toxin) Through Monkey Buccal Mucosa and Skin*. Toxicology Letters, 1991. **55**(2): p. 185-194.
86. Nielsen, H.M. and Rassing, M.R., *TR146 Cells Grown on Filters as a Model of Human Buccal Epithelium: IV. Permeability of Water, Mannitol, Testosterone and Beta-adrenoceptor Antagonists. Comparison to Human, Monkey and Porcine Buccal Mucosa*. International Journal of Pharmaceutics, 2000. **194**(2): p. 155-167.
87. Siegel, I.A. and Gordon, H.P., *Effects of Surfactants on the Permeability of Canine Oral-Mucosa In Vitro*. Toxicology letters, 1985. **26**(2-3): p. 153-158.
88. Koh, F.K., *The Pig Model For Biomedical-Research - Preface*. Federation Proceedings, 1982. **41**(2): p. 247-247.
89. Collins, P., Laffoon, J., and Squier, C., *Comparative Study Of Porcine Oral Epithelium*. J. Dent. Res, 1981. **60**: p. 543.
90. Squier, C.A. and Hall, B.K., *The Permeability of Skin and Oral-Mucosa to Water and Horseradish-Peroxidase as Related to the Thickness of the Permeability Barrier*. Journal of Investigative Dermatology, 1985. **84**(3): p. 176-179.
91. Lesch, C.A., Squier, C.A., Cruchley, A., et al., *The Permeability of Human Oral-Mucosa and Skin to Water*. Journal of Dental Research, 1989. **68**(9): p. 1345-1349.
92. Artusi, M., Santi, P., Colombo, P., et al., *Buccal Delivery of Thiocolchicoside: In Vitro and In Vivo Permeation Studies*. International Journal of Pharmaceutics, 2003. **250**(1): p. 203-213.
93. Devries, M.E., Bodde, H.E., Verhoef, J.C., et al., *Localization of The Permeability Barrier Inside Porcine Buccal Mucosa - A Combined In Vitro Study of Drug Permeability, Electrical-Resistance and Tissue Morphology*. International Journal of Pharmaceutics, 1991. **76**(1-2): p. 25-35.
94. Deneer, V.H.M., Drese, G.B., Roemele, P.E.H., et al., *Buccal Transport of Flecainide and Sotalol: Effect of a Bile Salt and Ionization State*. International Journal of Pharmaceutics, 2002. **241**(1): p. 127-134.
95. Ganem-Quintanar, A., Quintanar-Guerrero, D., Falson-Rieg, F., et al., *Ex vivo oral mucosal permeation of lidocaine hydrochloride with sucrose fatty acid esters as absorption enhancers*. International journal of pharmaceutics, 1998. **173**(1-2): p. 203-210.
96. Hansen, L.B., Christrup, L.L., and Bundgaard, H., *Enhanced Delivery of Ketobimidine Through Porcine Buccal Mucosa In Vitro Via More Lipophilic esters Prodrugs*. International Journal of Pharmaceutics, 1992. **88**(1-3): p. 237-242.
97. Hoogstraate, A.J., Senel, S., Cullander, C., et al., *Effects of Bile Salts on Transport Rates and Routes of FITC-labelled Compounds Across Porcine Buccal Epithelium In Vitro*. Journal of Controlled Release, 1996. **40**(3): p. 211-221.
98. Hoogstraate, A.J., Cullander, C., Nagelkerke, J.F., et al., *Diffusion Rates and Transport Pathways of Fluorescein Isothiocyanate (FITC)-Labeled Model Compounds Through Buccal Epithelium*. Pharmaceutical Research, 1994. **11**(1): p. 83-89.
99. Jasti, B.R., Zhou, S., Mehta, R.C., et al., *Permeability of Antisense Oligonucleotide Through Porcine Buccal Mucosa*. International Journal of Pharmaceutics, 2000. **208**(1-2): p. 35-39.
100. Le Brun, P.P.H., Fox, P.L.A., de Vries, M.E., et al., *In Vitro Penetration of Some [beta]-Adrenoreceptor Blocking Drugs Through Porcine Buccal Mucosa*. International Journal of Pharmaceutics, 1989. **49**(2): p. 141-145.
101. Nair, M.K., Chetty, D.J., Ho, H., et al., *Biomembrane Permeation of Nicotine: Mechanistic Studies with Porcine Mucosae and Skin*. Journal of Pharmaceutical Sciences, 1997. **86**(2): p. 257-262.
102. Nicolazzo, J.A., Reed, B.L., and Finnin, B.C., *The effect of various in vitro conditions on the permeability characteristics of the buccal mucosa*. Journal of pharmaceutical sciences, 2003. **92**(12): p. 2399-2410.
103. Nicolazzo, J.A., Reed, B.L., and Finnin, B.C., *Assessment of the effects of sodium dodecyl sulfate on the buccal permeability of caffeine and estradiol*. Journal of pharmaceutical sciences, 2004. **93**(2): p. 431-440.
104. Nicolazzo, J.A., Reed, B.L., and Finnin, B.C., *Modification of buccal drug delivery following pretreatment with skin penetration enhancers*. Journal of pharmaceutical sciences, 2004. **93**(8): p. 2054-63.
105. Nicolazzo, J.A., Reed, B.L., and Finnin, B.C., *Enhanced buccal mucosal retention and reduced buccal permeability of estradiol in the presence of padimate O and Azone (R): A mechanistic study*. Journal of pharmaceutical sciences, 2005. **94**(4): p. 873-882.
106. Nicolazzo, J.A., Reed, B.L., and Finnin, B.C., *Enhancing the buccal mucosal uptake and retention of triamcinolone acetonide*. Journal of Controlled Release, 2005. **105**(3): p. 240-248.

107. Senel, S., Duchene, D., Hincal, A.A., et al., *In Vitro Studies on Enhancing Effect of Sodium Glycocholate on Transbuccal Permeation of Morphine Hydrochloride*. Journal of Controlled Release, 1998. **51**(2-3): p. 107-113.
108. Senel, S., Kremer, M.J., Kas, S., et al., *Enhancing effect of chitosan on peptide drug delivery across buccal mucosa*. Biomaterials, 2000. **21**(20): p. 2067-2071.
109. Shin, S.C. and Kim, J.Y., *Enhanced Permeation of Triamcinolone Acetonide Through The Buccal Mucosa*. European Journal of Pharmaceutics and Biopharmaceutics, 2000. **50**(2): p. 217-220.
110. Shojaei, A.H., Berner, B., and Li, X.L., *Transbuccal Delivery of Acyclovir: I. In Vitro Determination of Routes of Buccal Transport*. Pharmaceutical Research, 1998. **15**(8): p. 1182-1188.
111. Shojaei, A.H., Khan, M., Lim, G., et al., *Transbuccal Permeation of a Nucleoside Analog, Dideoxycytidine: Effects of Menthol as a Permeation Enhancer*. International Journal of Pharmaceutics, 1999. **192**(2): p. 139-146.
112. Squier, C.A., Kremer, M.J., Bruskin, A., et al., *Oral mucosal permeability and stability of transforming growth factor beta-3 in vitro*. Pharmaceutical Research, 1999. **16**(10): p. 1557-1563.
113. Veuillez, F., Ganem-Quintanar, A., Deshusses, J., et al., *Comparison of The Ex-Vivo Oral Mucosal Permeation of Tryptophan-Leucine (Trp-Leu) and Its Myristoyl Derivative*. International Journal of Pharmaceutics, 1998. **170**(1): p. 85-91.
114. Veuillez, F., Rieg, F.F., Guy, R.H., et al., *Permeation of a Myristoylated Dipeptide Across The Buccal Mucosa: Topological Distribution and Evaluation of Tissue Integrity*. International Journal of Pharmaceutics, 2002. **231**(1): p. 1-9.
115. Xiang, J., Fang, X.L., and Li, X.L., *Transbuccal Delivery of 2',3'-Dideoxycytidine: In Vitro Permeation Study and Histological Investigation*. International Journal of Pharmaceutics, 2002. **231**(1): p. 57-66.
116. Squier, C.A., *Permeability Of Keratinized and Nonkeratinized Oral Epithelium to Horseradish-Peroxidase*. Journal of Ultrastructure Research, 1973. **43**(1-2): p. 160-177.
117. Squier, C.A. and Rooney, L., *Permeability Of Keratinized and Nonkeratinized Oral Epithelium to Lanthanum In Vivo*. Journal of Ultrastructure Research, 1976. **54**(2): p. 286-295.
118. Shojaei, A.H., Zhuo, S.L., and Li, X., *Transbuccal Delivery of Acyclovir (II): Feasibility, System Design, and In Vitro Permeation Studies*. J Pharm Pharm Sci, 1998. **1**(2): p. 66-73.
119. Imbert, D. and Cullander, C., *Assessment of Cornea Viability by Confocal Laser Scanning Microscopy and MTT Assay*. Cornea, 1997. **16**(6): p. 666-674.
120. Imbert, D. and Cullander, C., *Buccal Mucosa In Vitro Experiments I. Confocal Imaging of Vital Staining and MTT Assays for The Determination of Tissue Viability*. Journal of Controlled Release, 1999. **58**(1): p. 39-50.
121. Tavakolisaberi, M.R. and Audus, K.L., *Cultured Buccal Epithelium - An In Vitro Model Derived from The Hamster Pouch for Studying Drug Transport and Metabolism*. Pharmaceutical Research, 1989. **6**(2): p. 160-166.
122. Jacobsen, J., Pedersen, M., and Rassing, M.R., *TR146 Cells as a Model for Human Buccal Epithelium .2. Optimisation and Use of a Cellular Sensitivity MTS/PMS Assay*. International Journal of Pharmaceutics, 1996. **141**(1-2): p. 217-225.
123. Jacobsen, J., Vandeurs, B., Pedersen, M., et al., *TR146 Cells Grown on Filters as a Model for Human Buccal Epithelium .1. Morphology, Growth, Barrier Properties, and Permeability*. International Journal of Pharmaceutics, 1995. **125**(2): p. 165-184.
124. Nielsen, H.M. and Rassing, M.R., *TR146 Cells Grown on Filters as a Model of Human Buccal Epithelium: III. Permeability Enhancement by Different pH Values, Different Osmolality Values, and Bile Salts*. International Journal of Pharmaceutics, 1999. **185**(2): p. 215-225.
125. Nielsen, H.M. and Rassing, M.R., *TR146 Cells Grown on Filters as a Model of Human Buccal Epithelium: V. Enzyme Activity of The TR146 Cell Culture Model, Human Buccal Epithelium and Porcine Buccal Epithelium, and Permeability of Leu-enkephalin*. International Journal of Pharmaceutics, 2000. **200**(2): p. 261-270.
126. Rupniak, H., Rowlatt, C., Lane, E., et al., *Characteristics of Four New Human Cell Lines Derived From Squamous Cell Carcinomas of The Head and Neck*. Journal of the National Cancer Institute, 1985. **75**(4): p. 621.
127. Jacobsen, J., Nielsen, E.B., Brondum-Nielsen, K., et al., *Filter-grown TR146 Cells as an In Vitro Model of Human Buccal Epithelial Permeability*. European Journal of Oral Sciences, 1999. **107**(2): p. 138-146.
128. Nielsen, H.M. and Rassing, M.R., *Nicotine permeability across the buccal TR146 cell culture model and porcine buccal mucosa in vitro: effect of pH and concentration*. European Journal of Pharmaceutical Sciences, 2002. **16**(3): p. 151-157.
129. Nielsen, H.M., Verhoef, J.C., Ponec, M., et al., *TR146 Cells Grown on Filters as a Model of Human Buccal Epithelium: Permeability of Fluorescein Isothiocyanate-labelled Dextran in The Presence of Sodium Glycocholate*. Journal of Controlled Release, 1999. **60**(2-3): p. 223-233.
130. Selvaratnam, L., Cruchley, A.T., Navsaria, H., et al., *Permeability Barrier Properties of Oral Keratinocyte Cultures: a Model of Intact Human Oral Mucosa*. Oral Diseases, 2001. **7**(4): p. 252-258.

131. Aungst, A., *Permeability and Metabolism as Barriers to Transmucosal Delivery of Peptides and Proteins.*, in *Drug Permeation Enhancement. Theory and Applications.*, D.S. Hsieh, Editor. 1994, Marcel Dekker: New York. p. 323–343.
132. Lee, V. and Yamamoto, A., *Mucosal Penetration Enhancers for Facilitation of Peptide and Protein Drug Absorption.* Critical Reviews in Therapeutic Drug Carrier Systems, 1991. **8**(2): p. 91-192.
133. Adams, D., *The Mucus Barrier and Absorption Through The Oral Mucosa.* Journal of Dental Research, 1975. **54**(2 suppl): p. B19.
134. Squier, C. and Lesch, C., *Penetration Pathways Different Compounds Through Epidermis and Oral Epithelia.* Journal of Oral Pathology & Medicine, 1988. **17**(9 10): p. 512-516.
135. Hoogstraate, A., Senel, S., Cullander, C., et al., *Buccal Transport of Fluorescent Permeants: How Flux and Transport Pathways Depend on Permeant Size and Bile Salt Addition.* Brain, KR, James, VJ. Walters, KA (Eds.), Prediction of Percutaneous Penetration, 1993. **3**: p. 128—137.
136. Aungst, B.J., *Oral Mucosal Permeation Enhancement: Possibilities and Limitations*, in *Oral Mucosal Drug Delivery*, M.J. Rathbone, Editor. 1996, Marcel Dekker: New York. p. 65–83.
137. Swartzendruber, D., Manganaro, A., Madison, K., et al., *Organization of The Intercellular Spaces of Porcine Epidermal and Palatal Stratum Corneum: A Quantitative Study Employing Ruthenium Tetroxide.* Cell and tissue research, 1995. **279**(2): p. 271-276.
138. Egelrud, T. and Lundström, A., *Intercellular Lamellar Lipids in Plantar Stratum Corneum.* Acta dermato-venereologica, 1991. **71**(5): p. 369.
139. De Carvalho, M., Falson-Rieg, F., Eynard, I., Rojas, J., Lafforgue, C., Hadgraft, J., *Changes in Vehicle Composition During Skin Permeation Studies*, in *Prediction of Percutaneous Penetration*, K.R. Brain, James, V.J., Walters, K.A., Editor. 1993, STS: Cardiff. p. 251–254.
140. De Carvalho, M., Charasse, N., Falson-Rieg, F., Hadgraft, J., *Effect of Water Transport from The Receptor Compartment on The Percutaneous In Vitro Absorption of Estradiol.*, in *Prediction of Percutaneous Penetration*, K.R. Brain, James, V.J., Walters, K.A., Editor. 1996, STS: Cardiff. p. 286–289.
141. Ganem, A., Falson-Rieg, F., Buri, P., *Permeation Enhancement for Peptide Absorption Through The Palatal Mucosa.* Eur. J. Drug Metab. Pharmacokinet., 1996(Special Issue): p. 111.
142. Senel, S. and Hincal, A.A., *Drug Permeation Enhancement via Buccal Route: Possibilities and Limitations.* Journal of Controlled Release, 2001. **72**(1-3): p. 133-144.
143. Irie, T., Wakamatsu, K., Arima, H., et al., *Enhancing Effects of Cyclodextrins on Nasal Absorption of Insulin in Rats.* International Journal of Pharmaceutics, 1992. **84**(2): p. 129-139.
144. Schachter, H. and Williams, D., *Biosynthesis of mucus glycoproteins.* Advances in experimental medicine and biology, 1982. **144**: p. 3.
145. Szentkuti, L., Riedesel, H., Enss, M.L., et al., *Pre-epithelial mucus layer in the colon of conventional and germ-free rats.* The Histochemical Journal, 1990. **22**(9): p. 491-497.
146. Gottschalk, A., *Glycoproteins: Their composition, structure and function.* Vol. 5. 1972: Elsevier Pub. Co.
147. Gottschalk, A., *The chemistry and biology of sialic acids and related substances.* Vol. 89. 1960: Cambridge University Press London/England.
148. Chantler, E. and Scudder, P. *Terminal glycosylation in human cervical mucin.* 1984. Wiley Online Library.
149. Kornfeld, R. and Kornfeld, S., *Comparative aspects of glycoprotein structure.* Annual review of biochemistry, 1976. **45**(1): p. 217-238.
150. Scawen, M. and Allen, A., *The action of proteolytic enzymes on the glycoprotein from pig gastric mucus.* Biochemical Journal, 1977. **163**(2): p. 363.
151. Shojaei, A.H. and Li, X., *Mechanisms of buccal mucoadhesion of novel copolymers of acrylic acid and polyethylene glycol monomethylether monomethacrylate.* Journal of Controlled Release, 1997. **47**(2): p. 151-161.
152. Szycher, M., *High performance biomaterials: a comprehensive guide to medical and pharmaceutical applications.* 1991: CRC.
153. Lehr, C.M., Bouwstra, J.A., Boddé, H.E., et al., *A surface energy analysis of mucoadhesion: contact angle measurements on polycarbophil and pig intestinal mucosa in physiologically relevant fluids.* Pharmaceutical Research, 1992. **9**(1): p. 70-75.
154. Voyutskii, S.S., *Autohesion and adhesion of high polymers.* 1963: Interscience Publ.
155. Mikos, A.G. and Peppas, N.A., *Measurement of the surface tension of mucin solutions.* International journal of pharmaceutics, 1989. **53**(1): p. 1-5.
156. Ahagon, A. and Gent, A., *Effect of interfacial bonding on the strength of adhesion.* Journal of Polymer Science: Polymer Physics Edition, 1975. **13**(7): p. 1285-1300.
157. Salamat-Miller, N., Chittchang, M., and Johnston, T.P., *The Use of Mucoadhesive Polymers in Buccal Drug Delivery.* Advanced Drug Delivery Reviews, 2005. **57**(11): p. 1666-1691.